Table 5. Clinical trials testing TAA-derived peptides and/or full-length proteins as therapeutic interventions in patients affected by esophageal, gastric, pancreatic and colorectal carcinoma.
| Tumor type | Trials | Phase | Status | Type | TAAs | Co-therapy | Ref. |
|---|---|---|---|---|---|---|---|
| Colorectal carcinoma |
4 |
I |
Unknown |
Peptide |
RNF43 |
As single AA |
NCT00641615 |
| II |
Recruiting |
GI-4000 |
Combined with bevacizumab and/or FOLOFOX or FOLFIRI |
NCT01322815 |
|||
| MUC1 |
Combined with chemoradio-therapy and cyclophosphamide |
NCT01507103 |
|||||
| Combined with poly ICLC |
NCT00773097 |
||||||
| Esophageal carcinoma |
5 |
I |
Active, not recruiting |
FL protein |
NY-ESO-1 |
As single AA complexed with CHP |
NCT01003808 |
| Unknown |
Peptide |
IMP3 LY6K TTK |
As single AA |
NCT00682227 |
|||
| KOC1 TTK URLC10 VEGFR1/2 |
Combined with cisplatin and 5-FU |
NCT00632333 |
|||||
| I-II |
Recruiting |
TTK URLC10 |
Combined with CpG ODNs |
NCT00669292 |
|||
| II |
CDCA1 KOC1 URLC10 |
As single AA |
NCT01267578 |
||||
| Gastric cancer |
1 |
I-II |
Recruiting |
Peptide |
VEGFR1 |
As single AA |
NCT01227772 |
| Pancreatic carcinoma | 5 | I |
Active, not recruiting |
Peptide | hTERT |
Combined with gemcitabine, GM-CSF and tadalafil |
NCT01342224 |
| VEGFR1/2 |
Combined with gemcitabine |
NCT01266720 |
|||||
| Unknown |
NCT00639925 |
||||||
| I-II | VEGFR1 |
As single AA |
NCT00683358 |
||||
| VEGFR1/2 | Combined with gemcitabine | NCT00655785 |
Abbreviations: 5-FU, 5-fluorouracil; AA, adjuvanted agent; CDCA1, cell division cycle-associated 1; CHP, cholesterol-bearing hydrophobized pullulan; FL, full-length; FOLFIRI, folinic acid, 5-FU, irinotecan; FOLFOX, folinic acid, 5-FU, oxaliplatin; GM-CSF, granulocyte macrophage colony-stimulating factor; hTERT, human telomerase reverse transcriptase; IMP3, insulin-like growth factor II mRNA-binding protein 3; KOC1, K homology domain containing protein overexpressed in cancer; LY6K, lymphocyte antigen 6 complex locus K; MUC1, mucin 1; ODN, oligodeoxynucleotide; poly ICLC, polyriboinosinic-polyribocytidylic acid stabilized with poly-L-lysine in carboxymethylcellulose; TAA, tumor associated antigen; URLC10, upregulated in lung cancer 10; VEGFR, vascular endothelial growth factor receptor. *started after January, 1st 2008 and not withdrawn, terminated or completed at the day of submission.